The Role of Antiviral Treatment of Influenza in Reducing Hospitalizations and Other Severe Outcomes: A Need for More Evidence
- 14 November 2025
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Abstract
More evidence is needed to define the benefits and role of antiviral treatment to reduce risk of severe influenza outcomes based on clinical risk factors and timing. Well-conducted real-world observational studies can complement evidence from randomized controlled trials to address critical gaps.Keywords
This publication has 26 references indexed in Scilit:
- Influenza With and Without Oseltamivir Treatment and Neuropsychiatric Events Among Children and AdolescentsJAMA Neurology, 2025
- Oseltamivir Treatment vs Supportive Care for Seasonal Influenza Requiring HospitalizationJAMA Network Open, 2025
- Antiviral Medications for Treatment of Nonsevere InfluenzaJAMA Internal Medicine, 2025
- Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trialsThe Lancet, 2024
- Oseltamivir May or May Not Reduce HospitalizationsJAMA Internal Medicine, 2024
- Oseltamivir May or May Not Reduce HospitalizationsJAMA Internal Medicine, 2024
- Evaluation of Oseltamivir Used to Prevent Hospitalization in Outpatients With InfluenzaJAMA Internal Medicine, 2024
- Baloxavir Marboxil for Uncomplicated Influenza in Adults and AdolescentsNew England Journal of Medicine, 2018
- Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trialsThe Lancet, 2015
- Use of the Oral Neuraminidase Inhibitor Oseltamivir in Experimental Human InfluenzaJAMA, 1999